David Whiteley

David Whiteley

Dr David Whiteley

Lecturer

Biography

Dave trained in adult nursing at the University of Dundee, achieving his registration in 2005. Since then, he has built a career within the fields of infectious diseases, sexual health and blood-borne viruses. In 2014 he developed his interest in health research by undertaking a PhD, successfully completing this three years later. Dave joined the School of Health and Social Care at Edinburgh Napier University in 2017, and in 2019 was awarded a £200,000 grant from the CSO to build on his doctoral research exploring the delivery of hepatitis C treatment to people who inject drugs. He also lectures on the undergraduate nursing programme, and is deputy-programme lead for the Graduate Certificate in Sexual and Reproductive Health, which was nominated for a Student Nursing Times Award in 2018.

Themes

Research Areas

Esteem

Conference Activity

  • 8th International Conference for on Hepatitis Care in Substance Users. Montreal, 11th - 13th September 2019 (Delegate)
  • 9th International Conference on Hepatitis Care in Substance Users (Invited Social Science Research theme co-chair) - DELAYED BY COVID-19 UNTIL 2021
  • 5th International Symposium of Hepatitis Care in Substance Users, Oslo, 7th - 9th September 2016 (Awarded New Investigator Scholarship)

 

Fellowships and Awards

  • Shortlisted for Scottish NMAHP 2017 'Originality of Doctoral Research' Award
  • Edinburgh Napier University Research Conference 2016 - 3 Minute Thesis Winner

 

Invited Speaker

  • Faculty of Sexual and Reproductive Healthcare Annual Scientific Meeting. Brighton, 20th-21st April 2020 - Cancelled due to COVID-19
  • Viral Hepatitis Symposium Scotland, Edinburgh, November 2017

 

Reviewing

  • Invited peer reviewer for Addiction
  • Invited peer reviewer for Public Health
  • Invited peer reviewer for the International Journal of Drug Policy
  • Invited peer reviewer for Drug and Alcohol Review
  • Invited peer reviewer for BMC Health Services Research
  • Invited peer reviewer for the International Symposium on Hepatitis Care in Substance Users
  • Invited peer reviewer for Health and Quality of Life Outcomes

 

Date


9 results

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)

Journal Article
Hickman, M., Dillon, J. F., Elliott, L., De Angelis, D., Vickerman, P., Foster, G., …Hutchinson, S. J. (2019)
Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). BMJ Open, 9(9), https://doi.org/10.1136/bmjopen-2019-029538
Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people curren...

Hepatitis C in a new therapeutic era: Recontextualising the lived experience

Journal Article
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2017)
Hepatitis C in a new therapeutic era: Recontextualising the lived experience. Journal of Clinical Nursing, https://doi.org/10.1111/jocn.14083
Aims and Objectives To explore the experience of adults living with hepatitis C in a new era of interferon-free treatment. Background Hepatitis C is a leading cause of morbidi...

The Lived Experience of Interferon-free Treatments for Hepatitis C: A Thematic Analysis

Presentation / Conference
Whiteley, D., Whittaker, A., Elliott, L. & Cunningham-Burley, S. (2017, March)
The Lived Experience of Interferon-free Treatments for Hepatitis C: A Thematic Analysis. Poster presented at NHS Lothian R&D Conference 2017, Edinburgh
no abstract available.

Recontextualising the lived experience of hepatitis C and its treatment

Thesis
Whiteley, D. J. (2016)
Recontextualising the lived experience of hepatitis C and its treatment. (Thesis). Edinburgh Napier University. Retrieved from http://researchrepository.napier.ac.uk/Output/979740
BACKGROUND: Rapid advances in the treatment of the hepatitis C virus (HCV) have been witnessed in clinical practice over the last five years. Pharmacological developments have...

The lived experience of interferon-free treatments for hepatitis C: A thematic analysis

Journal Article
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2016)
The lived experience of interferon-free treatments for hepatitis C: A thematic analysis. International Journal of Drug Policy, 38, 21-28. https://doi.org/10.1016/j.drugpo.2016.10.013
Background: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduc...

Qualitative insights into the lived experience of interferon-free treatments

Presentation / Conference
Whiteley, D. (2016, September)
Qualitative insights into the lived experience of interferon-free treatments. Paper presented at 5th International Symposium on Hepatitis Care in Substance Users, Oslo, Norway
BACKGROUND: Previous research has focused on the experience of individuals undergoing interferon (IFN) based treatment for hepatitis C (HCV), however qualitative insights into...

Health-Related Quality of Life for individuals with hepatitis C: A narrative review

Journal Article
Whiteley, D., Elliott, L., Cunningham-Burley, S., & Whittaker, A. (2015)
Health-Related Quality of Life for individuals with hepatitis C: A narrative review. International Journal of Drug Policy, 26(10), 936-949. https://doi.org/10.1016/j.drugpo.2015.04.019
BACKGROUND The assessment of Health-Related Quality of Life (HRQoL) in hepatitis C (HCV) infected individuals continues to gain importance. However, rarely do reviews of this...

Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals attending an HIV clinic

Presentation / Conference
Whiteley, D. (2011, April)
Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals attending an HIV clinic. Poster presented at 17th Annual Conference of the British HIV Association (BHIVA
Poster abstracts.

Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens

Presentation / Conference
Devine, K., Whiteley, D., & Leen, C. Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens

)
Devine, K., Whiteley, D., & Leen, C. Audit of eligibility of hepatitis C/HIV co-infected patients in the Lothian Regional Infectious Diseases Unit cohort for new HCV protease inhibitor containing regimens
Background: Introduction of the new HCV protease inhibitors has been shownto improve outcomes for mono-infected patients. Recent data showssignificant decline in HCV RNA at 24...

Current Post Grad projects

Previous Post Grad projects